![Foto de EDUARDO](/img/nophoto.png)
EDUARDO
DÍAZ-RUBIO GARCÍA
Chercheur jusqu' 2020
Publications (446) Publications de EDUARDO DÍAZ-RUBIO GARCÍA
2024
-
El cáncer, el gran reto de la medicina moderna: Importancia de estos diez últimos años y las perspectivas de futuro
El Cronista del Estado Social y Democrático de Derecho, Núm. 112, pp. 52-57
-
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
European Journal of Cancer, Vol. 207
2023
-
Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials
Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230
-
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 21, pp. 3663-3669
-
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Cancers, Vol. 15, Núm. 16
-
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
European Journal of Cancer, Vol. 190
2022
-
Association of miR-21 and miR-335 to microsatellite instability and prognosis in stage III colorectal cancer
Cancer Biomarkers, Vol. 34, Núm. 2, pp. 201-210
-
Molecular Classification of Colorectal Cancer by microRNA Profiling: Correlation with the Consensus Molecular Subtypes (CMS) and Validation of miR-30b Targets
Cancers, Vol. 14, Núm. 21
-
Real Academia Nacional de Medicina de España
Las Reales Academias Nacionales en Madrid (Instituto de Estudios Madrileños), pp. 157
-
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132
2021
-
Behavioural and structural interventions in cancer prevention: towards the 2030 SDG horizon
Molecular Oncology, Vol. 15, Núm. 3, pp. 801-808
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Therapeutic Advances in Medical Oncology, Vol. 13
-
Implementation of the Quality Oncology Practice Initiative Program in Spain: First Results and Implications
JCO oncology practice, Vol. 17, Núm. 8, pp. e1162-e1169
-
Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study
ESMO open, Vol. 6, Núm. 2, pp. 100062
-
Management and perception of therapeutic adherence of breakthrough cancer pain by oncologists in Spain
Revista de la Sociedad Espanola del Dolor, Vol. 28, pp. 19-26
-
Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis
Cancer Treatment Reviews, Vol. 99
2020
-
Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected
Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116
-
Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials (ESMO Open (2019) 4 (e000599) DOI: 10.1136/esmoopen-2019-000599
ESMO Open
-
SOD3 induces a HIF-2α-dependent program in endothelial cells that provides a selective signal for tumor infiltration by T cells
Journal for immunotherapy of cancer, Vol. 8, Núm. 1